Cas:203201-43-8 2-bromo-3-hydroxy-4-nitrobenzonitrile manufacturer & supplier

We serve Chemical Name:2-bromo-3-hydroxy-4-nitrobenzonitrile CAS:203201-43-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-bromo-3-hydroxy-4-nitrobenzonitrile

Chemical Name:2-bromo-3-hydroxy-4-nitrobenzonitrile
CAS.NO:203201-43-8
Synonyms:2-bromo-3-cyano-6-nitrophenol;2-bromo-3-hydroxy-4-nitro-benzonitrile
Molecular Formula:C7H3BrN2O3
Molecular Weight:243.01400
HS Code:2926909090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:325.7ºC at 760 mmHg
Density:1.98g/cm3
Index of Refraction:1.686
PSA:89.84000
Exact Mass:241.93300
LogP:2.45778

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-bromo-3-cyano-6-nitrophenol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-bromo-3-hydroxy-4-nitro-benzonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-bromo-3-hydroxy-4-nitro-benzonitrile Use and application,2-bromo-3-cyano-6-nitrophenol technical grade,usp/ep/jp grade.


Related News: Compared to white women, Black women are more likely to be diagnosed with breast cancer before age 50 or with estrogen receptor (ER)-negative and triple-negative breast cancer. 2-bromo-3-hydroxy-4-nitrobenzonitrile manufacturer API and raw material are often confused due to the similar usage of the two terms. 2-bromo-3-hydroxy-4-nitrobenzonitrile supplier Compared to white women, Black women are more likely to be diagnosed with breast cancer before age 50 or with estrogen receptor (ER)-negative and triple-negative breast cancer. 2-bromo-3-hydroxy-4-nitrobenzonitrile vendor Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). 2-bromo-3-hydroxy-4-nitrobenzonitrile factory The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured.